Background. Emerging evidence suggests that nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery diseases\nand arrhythmias. The FibroScan (Echosens, France), a widely available, noninvasive device, is able to detect liver fibrosis and\nsteatosis within this patient population. However, the FibroScan is currently contraindicated in patients with cardiac pacemakers\n(PM) or implantable cardioverter-defibrillators (ICD). Objective. To determine the safety profile of FibroScan testing in patients\nwith PM or ICD. Methods. Consecutive outpatients undergoing routine device interrogations at a tertiary level teaching hospital\nunderwent simultaneous liver stiffness measurements. PM or ICD performance data, device types, patient demographics, medical\nhistory, and previous laboratory and conventional liver imaging results were collected. Results. Analysis of 107 subjects with 33\ndifferent types of implanted cardiac devices, from 5 different companies (Medtronic, Sorin, ELA Medical, Boston Scientific, and\nSt. Jude), did not demonstrate any adverse events as defined by abnormal device sensing/pacing or ICD firing. This population\nincluded high risk subjects undergoing active pacing (
Loading....